Pro-inflammatory cytokine and inflammatory signaling pathways

Pro-inflammatory cytokine and inflammatory signaling pathways represent a complex network of secreted proteins and intracellular cascades that coordinate the body's response to injury and infection [StatPearls, 2023]. Central to these pathways are cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which act as primary messengers to initiate and amplify inflammatory responses [Nature Reviews Immunology, 2017]. Upon binding to their respective receptors, these cytokines activate downstream mediators including the Nuclear Factor-kappa B (NF-κB), Mitogen-Activated Protein Kinase (MAPK), and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathways [PubMed, 2021]. Chronic overactivation of these signaling networks is a hallmark of numerous pathologies, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease [NIH, 2022]. Pharmacological modulation of these pathways typically involves biological agents that neutralize specific cytokines or small-molecule inhibitors that target intracellular signaling enzymes [Journal of Clinical Investigation, 2018]. While highly effective, these therapies carry risks of immunosuppression and increased susceptibility to serious infections due to the essential role of these pathways in normal host defense [Lancet, 2019].

Other names

Inflammatory signaling cascadePro-inflammatory cytokine networkCytokine-mediated signalingInflammatory mediators

Therapeutic agents modulate these pathways by neutralizing pro-inflammatory cytokines, blocking their cognate receptors, or inhibiting intracellular signaling components such as Janus kinases (JAKs) and the NF-κB transcription factor complex [StatPearls, 2023; Nature Reviews Drug Discovery, 2017].